FDA Commissioner Marty Makary has stated that he believes everything should be over the counter. This applies to drugs unless they are dangerous, addictive or require medical monitoring. The article mentions the FDA's enforcement of OTC drugs. It also addresses new standards for trial studies. In 2026, the FDA expects to approve several drugs, such as Eli Lilly's oral orforgliprone in March for the treatment of obesity. Other candidates include Takeda's oveporexton for narcolepsy and Zycubo for Menkes disease approved on January 1, 2026. Adquey for mild to moderate atopic dermatitis was approved on February 12, 2026.[2] The oral GLP-1 market is expected to comprise 20% of the $80 billion obesity drug market by the end of the decade.[1]